Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Merger or Acquisition (July 2016)

8 slides from Sucampo Pharmaceuticals's merger presentation, Jul 11, 2016

  1. Slide 1: See accompanying Notes to unaudited pro forma combined consolidated

    See accompanying Notes to unaudited pro forma combined consolidated financial information.

  2. Slide 2: See accompanying Notes to unaudited pro forma combined consolidated

    See accompanying Notes to unaudited pro forma combined consolidated financial information.

  3. Slide 3: See accompanying Notes to unaudited pro forma combined consolidated

    See accompanying Notes to unaudited pro forma combined consolidated financial information.

  4. Slide 4: Conforming schedules of historical statement of income (loss) of R-Tech

    Conforming schedules of historical statement of income (loss) of R-Tech for the nine months ended September 30, 2015 (in thousands):

  5. Slide 5: Conforming schedules of historical balance sheet of R-Tech 2015

    Conforming schedules of historical balance sheet of R-Tech as of September 30, 2015 (in thousands, except share and per share data):

  6. Slide 6: Business combination accounted for using the acquisition method (ASC 805)

    The business combination of Sucampo and R-Tech has been accounted for using the acquisition method of accounting under the provisions of ASC 805, with Sucampo representing the accounting acquirer. Accordingly, the historical financial statements have been adjusted to give effect to the impact of the

  7. Slide 7: Summary of the preliminary allocation of the purchase price

    The following is a summary of the preliminary allocation of the above purchase price as reflected in the unaudited pro forma combined consolidated balance sheet as of September 30, 2015 (amounts in thousands):

  8. Slide 8: Goodwill and Note 5 pro forma balance sheet adjustments

    The goodwill balance is primarily attributed to the assembled workforce, expanded market opportunities and cost and other operating synergies anticipated upon the integration of the operations of Sucampo and R-Tech. Note 5 – Unaudited Pro Forma Combined Consolidated Balance Sheet Adjustments Purchas

Sucampo Pharmaceuticals — Merger or Acquisition (July 2016) on 6ix